Longevity, aging and rapamycin

Cellular and Molecular Life Sciences

Volumn 71, Issue 22, 2014, Pages 4325-4346

  Ehninger, Dan ^a   Neff, Frauke ^b   Xie, Kan ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Aging; Anti aging; Cancer; Cardiovascular disease; Disease; Drug; Lifespan; Longevity; Mammalian target of rapamycin; Mammals; Mechanism; Mice; mTOR; Neurodegeneration; Prevention; Rapamycin; Treatment

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; TARGET OF RAPAMYCIN KINASE;

AGING; BIOLOGICAL TRAIT; COGNITIVE DEFECT; DEATH; GENE EXPRESSION; HEART FUNCTION; HEMATOLOGY; IMMUNOLOGY; LIFE EXTENSION; LIFESPAN; LOCOMOTION; LONGEVITY; MENTAL DETERIORATION; MENTAL PERFORMANCE; METABOLISM; NONHUMAN; OPHTHALMOLOGY; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION; SKELETON; SYMPTOM; TENDON; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; NERVE CELL;

MAMMALIA; MUS;

AGING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; LONGEVITY; NEURONS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84929370242     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1677-1     Document Type: Review

References (79)

1. Olshansky SJ, Perry D, Miller RA, Butler RN (2006) In pursuit of the longevity dividend. Scientist 20:28-35
2. Blagosklonny MV (2007) An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 12(5-6):218-224. doi: 10.1016/j.drudis.2007.01.004
3. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L (2010) With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 11(6):453-465. doi: 10.1016/j.cmet.2010.05.001
4. Blagosklonny MV (2006) Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5(18):2087-2102 (pii: 3288)
5. Ehninger D (2013) From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 68:97-105 (Pii:S0028-3908(12)00200-6)
6. Kaeberlein M, Powers RW 3rd, Steffen KK, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S, Kennedy BK (2005) Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310(5751):1193-1196
7. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F (2003) Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426(6967):620
8. Jia K, Chen D, Riddle DL (2004) The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131(16):3897-3906. doi: 10.1242/dev.01255
9. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S (2004) Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 14(10):885-890
10. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460(7253):392-395
11. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66(2):191-201. doi: 10.1093/gerona/glq178
12. Chen C, Liu Y, Zheng P (2009) mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2(98):ra75. doi: 10.1126/scisignal.2000559
13. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, Holter SM, Moreth K, Prehn C, Puk O, Racz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, Hofler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Ehninger D (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123(8):3272-3291. doi: 10.1172/JCI67674
14. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230-4236. doi: 10.4161/cc.10.24.18486
15. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L, Strong R (2013) Rapamycin-mediated lifespan increase in mice is dose and sex-dependent and appears metabolically distinct from dietary restriction. Aging Cell. doi: 10.1111/acel.12194
16. Leslie M (2013) Biomedicine a putative antiaging drug takes a step from mice to men. Science 342(6160):789. doi: 10.1126/science.342.6160.789
17. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T (2013) Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep 4(5):913-920. doi: 10.1016/j.celrep.2013.07.030
18. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA (2012) Rapamycin slows aging in mice. Aging Cell. doi: 10.1111/j.1474-9726.2012.00832.x
19. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, Kapahi P, Nelson MD, Kennedy BK, Melov S (2013) Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12(5):851-862. doi: 10.1111/acel.12109
20. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11(2):326-335. doi: 10.1111/j.1474-9726.2011.00791.x
21. Halloran J, Hussong S, Burbank R, Podlutskaya N, Fischer K, Sloane L, Austad SN, Strong R, Richardson A, Hart M, Galvan V (2012) Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. doi: 10.1016/j.neuroscience.2012.06.054
22. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, Rendon S, van Remmen H, Ward W, Javors M, Richardson A, Austad SN, Fischer K (2013) Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. doi: 10.1093/gerona/glt056
23. Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37(Pt 1):217-222. doi: 10.1042/BST0370217
24. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4(9):648-657
25. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10(1):151-162
26. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102(24):8573-8578
27. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121(2):179-193
28. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5):577-590
29. Klann E, Dever TE (2004) Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 5(12):931-942
30. Costa-Mattioli M, Sonenberg N, Richter JD (2009) Translational regulatory mechanisms in synaptic plasticity and memory storage. Prog Mol Biol Transl Sci 90:293-311. doi: 10.1016/S1877-1173(09)90008-4
31. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C (2007) Lifespan extension by conditions that inhibit translation in caenorhabditis elegans. Aging Cell 6(1):95-110. doi: 10.1111/j.1474-9726.2006.00267.x
32. Syntichaki P, Troulinaki K, Tavernarakis N (2007) eIF4E function in somatic cells modulates ageing in caenorhabditis elegans. Nature 445(7130):922-926. doi: 10.1038/nature05603
33. Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, Lithgow GJ, Kapahi P (2007) Inhibition of mRNA translation extends lifespan in caenorhabditis elegans. Aging Cell 6(1):111-119. doi: 10.1111/j.1474-9726.2006.00266.x
34. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326(5949):140-144. doi: 10.1126/science.1177221
35. Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132-141. doi: 10.1038/ncb2152
36. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C (2008) A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet 4(2):e24. doi: 10.1371/journal.pgen.0040024
37. Zhang C, Cuervo AM (2008) Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 14(9):959-965. doi: 10.1038/nm.1851
38. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098-1101
39. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22(2):159-168
40. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, Yonezawa K (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9(4):359-366. doi: 10.1111/j.1356-9597.2004.00727.x
41. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, Carr MD (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27(5):585-595. doi: 10.1038/sj.onc.1210693
42. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2(67):pe24. doi: 10.1126/scisignal.267pe24
43. Blackwell BN, Bucci TJ, Hart RW, Turturro A (1995) Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL6 mice fed NIH-31 open formula diet. Toxicol Pathol 23(5):570-582
44. Brayton CF, Treuting PM, Ward JM (2012) Pathobiology of aging mice and GEM: background strains and experimental design. Vet Pathol 49(1):85-105. doi: 10.1177/0300985811430696
45. Pettan-Brewer C, Treuting PM (2011) Practical pathology of aging mice. Pathobiol Aging Age relat Dis 1:7202
46. Lipman R, Galecki A, Burke DT, Miller RA (2004) Genetic loci that influence cause of death in a heterogeneous mouse stock. J Gerontol A Biol Sci Med Sci 59(10):977-983 (pii: 59/10/B977)
47. Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19(56):6680-6686. doi: 10.1038/sj.onc.1204091
48. Garber K (2001) Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 93(20):1517-1519
49. Panwalkar A, Verstovsek S, Giles FJ (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100(4):657-666. doi: 10.1002/cncr.20026
50. Kopelovich L, Fay JR, Sigman CC, Crowell JA (2007) The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomark Prev 16(7):1330-1340. doi: 10.1158/1055-9965.EPI-07-0045
51. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883-889 (pii: 00007890-200510150-00003)
52. Elghazi L, Weiss AJ, Barker DJ, Callaghan J, Staloch L, Sandgren EP, Gannon M, Adsay VN, Bernal-Mizrachi E (2009) Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 136(3):1091-1103. doi: 10.1053/j.gastro.2008.11.043
53. Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, Depinho RA (2008) Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 28(7):2414-2425. doi: 10.1128/MCB.01621-07
54. Blagosklonny MV (2012) Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther 13(14):1349-1354. doi: 10.4161/cbt.22859
55. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV (2010) Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 176(5):2092-2097. doi: 10.2353/ajpath.2010.091050
56. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP (2012) New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) 4(10):715-722 (pii: 100496)
57. Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD (2014) eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 7(1):169-178. doi: 10.1158/1940-6207.CAPR-13-0299
58. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, Hubbard G, Hasty P, Sharp ZD (2013) Rapamycin extends life span of Rb1±mice by inhibiting neuroendocrine tumors. Aging (Albany NY) 5(2):100-110 (pii: 100533)
59. Miller RA (2009) Biology of aging and longevity. In: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S (eds) Hazzard's geriatric medicine and gerontology. McGraw Hill, New York
60. Kennard JA, Woodruff-Pak DS (2011) Age sensitivity of behavioral tests and brain substrates of normal aging in mice. Front Aging Neurosci 3:9. doi: 10.3389/fnagi.2011.00009
61. Magnusson KR (2001) Influence of diet restriction on NMDA receptor subunits and learning during aging. Neurobiol Aging 22(4):613-627 (pii: S019745800000258X)
62. Napoli KL, Wang ME, Stepkowski SM, Kahan BD (1997) Distribution of sirolimus in rat tissue. Clin Biochem 30(2):135-142 (pii: S0009-9120(96)00157-9)
63. Murphy GG, Rahnama NP, Silva AJ (2006) Investigation of age-related cognitive decline using mice as a model system: behavioral correlates. Am J Geriatr Psychiatry 14(12):1004-1011
64. Ingram DK (1983) Toward the behavioral assessment of biological aging in the laboratory mouse: concepts, terminology, and objectives. Exp Aging Res 9(4):225-238. doi: 10.1080/03610738308258457
65. Harding JJ (2003) Aging of the eye. In: Aspinall R (ed) Aging of organs and systems. Kluwer Academic Publishers, Netherlands, pp 179-200
66. Dai DF, Rabinovitch PS (2009) Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc Med 19(7):213-220. doi: 10.1016/j.tcm.2009.12.004
67. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S (2002) Changes in bone structure and mass with advancing age in the male C57BL/6 J mouse. J Bone Miner Res 17(6):1044-1050. doi: 10.1359/jbmr.2002.17.6.1044
68. Frith CH, Suber RL, Umholtz R (1980) Hematologic and clinical chemistry findings in control BALB/c and C57BL/6 mice. Lab Anim Sci 30(5):835-840
69. Leuenberger HG, Kunstyr I (1976) Gerontological data of C57BL/6 J mice. II. Changes in blood cell counts in the course of natural aging. J Gerontol 31(6):648-653
70. Diekmann F, Rovira J, Diaz-Ricart M, Arellano EM, Vodenik B, Jou JM, Vives-Corrons JL, Escolar G, Campistol JM (2012) mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant 27(2):537-541. doi: 10.1093/ndt/gfr318
71. Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA (2011) Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117(4):1228-1238. doi: 10.1182/blood-2010-05-287821
72. Kempermann G, Kuhn HG, Gage FH (1998) Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci 18(9):3206-3212
73. Romero-Suarez S, Shen J, Brotto L, Hall T, Mo C, Valdivia HH, Andresen J, Wacker M, Nosek TM, Qu CK, Brotto M (2010) Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age and its loss accelerates skeletal muscle aging process by altering calcium homeostasis. Aging (Albany NY) 2(8):504-513 (pii: 100190)
74. Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Curr Biol 19(22):R1046-R1052. doi: 10.1016/j.cub.2009.09.058
75. Kmiec Z, Kotlarz G, Smiechowska B, Mysliwski A (1998) The effect of fasting and refeeding on thyroid follicule structure and thyroid hormone levels in young and old rats. Arch Gerontol Geriatr 26(2):161-175 (pii: S0167-4943(97)00040-X)
76. McCampbell AS, Harris HA, Crabtree JS, Winneker RC, Walker CL, Broaddus RR (2010) Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. Cancer Prev Res (Phila) 3(3):290-300. doi: 10.1158/1940-6207.CAPR-09-0199
77. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, Javors M, Wood WH 3rd, Becker KG, Perez VI, Richardson A (2014) Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS ONE 9(1):e83988. doi: 10.1371/journal.pone.0083988
78. Fok WC, Bokov A, Gelfond J, Yu Z, Zhang Y, Doderer M, Chen Y, Javors M, Wood WH 3rd, Becker KG, Richardson A, Perez VI (2013) Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver. Aging Cell 13(2):311-319. doi: 10.1111/acel.12175
79. Ehninger D, Silva AJ (2011) Rapamycin for treating Tuberous sclerosis and autism spectrum disorders. Trends Mol Med 17(2):78-87. doi: 10.1016/j.molmed.2010.10.002